Ocular Therapeutix, Inc. reported $52M of revenue over the trailing twelve months, −8.1% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $52M (to Q2 2026). Net income: −$301M, trailing twelve months to Q2 2026. Free cash flow: −$255M, trailing twelve months to Q2 2026. Operating margin: −618%, trailing twelve months to Q2 2026.

OCULOcular Therapeutix, Inc.

Healthcare

$7.53-38% 1Y

$7.53

$6.8852 weeks$16.11

OCUL as reported

Ocular Therapeutix, Inc. reported $52M of revenue over the trailing twelve months, −8.1% on the year before. 10 reported series are charted on this page, each one as filed.

$52M

Revenue, trailing twelve months · to Q2 2026 · −8.1% against the twelve months before

Net income: −$301M
Net income · +39% year on year · trailing twelve months to Q2 2026
Free cash flow: −$255M
Free cash flow · +42% year on year · trailing twelve months to Q2 2026
Operating margin: −618%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for OCUL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$52M	−8.1%	Q2 2026
Net income	−$301M	+39%	Q2 2026
EPS	−$1.40	+10%	Q2 2026
Gross margin	87%	n/a	Q2 2026
Operating margin	−618%	n/a	Q2 2026
Net margin	−593%	n/a	Q2 2026
ROE	−61%	n/a	Q2 2026
ROA	−45%	n/a	Q2 2026
ROIC	59%	n/a	Q3 2021 · 19 quarters behind
Free cash flow	−$255M	+42%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.